^Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility”.European Journal of Pharmacology.411 (3): 289—99.PMID11164387.doi:10.1016/S0014-2999(00)00897-9.
^Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells”.European Journal of Pharmacology.481 (1): 41—50.PMID14637173.doi:10.1016/j.ejphar.2003.09.013.
^Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). „Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration”.Methods and findings in experimental and clinical pharmacology.19 (5): 343—50.PMID9379783.
^Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”.European Journal of Pharmacology.332 (2): 183—93.PMID9286620.doi:10.1016/S0014-2999(97)01073-X.
^Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). „The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia”.Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences.36 (2): 101—8.PMID9757621.
^Petkov, VD; Belcheva, S; Konstantinova, E (1995). „Anxiolytic effects of dotarizine, a possible antimigraine drug”.Methods and findings in experimental and clinical pharmacology.17 (10): 659—68.PMID9053586.
^Lazarova, M; Petkova, B; Petkov, VD (1995). „Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats”.Methods and findings in experimental and clinical pharmacology.17 (1): 53—8.PMID7623521.